Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents. 2015

Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica, Taichung 40402, Taiwan, ROC; School of Pharmacy, China Medical University, Taichung 40402, Taiwan, ROC.

In our previous studies on 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) analogs, we synthesised numerous substituted carbazole and α-carboline derivatives, which exhibited anticancer activity. In this study, we designed and synthesised a series of 3,9-substituted β-carbolines, by replacing the tricyclic rings of carbazole and α-carboline derivatives with isosteric β-carboline, and evaluated anticancer activity. We observed that 9-(2-methoxybenzyl)-β-carboline-3-carboxylic acid (11a) inhibited the growth of HL-60 cells by inducing apoptosis, with a half maximal inhibitory concentration of 4.0 μM. Our findings indicate that β-carboline derivatives can be used as lead compounds for developing novel antitumor agents.

UI MeSH Term Description Entries
D002243 Carbolines A group of pyrido-indole compounds. Included are any points of fusion of pyridine with the five-membered ring of indole and any derivatives of these compounds. These are similar to CARBAZOLES which are benzo-indoles. Carboline,Pyrido(4,3-b)Indole,Beta-Carbolines,Pyrido(4,3-b)Indoles,Beta Carbolines
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
May 2024, Bioorganic & medicinal chemistry letters,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
April 2011, European journal of medicinal chemistry,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
January 2019, Frontiers in chemistry,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
December 2010, Bioorganic & medicinal chemistry,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
March 2010, Oncology letters,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
August 2013, Drug discoveries & therapeutics,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
August 2018, Molecules (Basel, Switzerland),
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
July 2017, European journal of medicinal chemistry,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
December 2018, Future medicinal chemistry,
Yi-Fong Chen, and Yi-Chien Lin, and Jeng-Pang Chen, and Hsu-Chin Chan, and Mei-Hua Hsu, and Hui-Yi Lin, and Sheng-Chu Kuo, and Li-Jiau Huang
January 2015, European journal of medicinal chemistry,
Copied contents to your clipboard!